Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Rhea-AI Summary

Aclaris Therapeutics (NASDAQ: ACRS) will participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference on April 14, 2026 at 12:00 PM EDT.

CEO Dr. Neal Walker and senior leaders will join a fireside chat; a live webcast and archived replay will be available on the company website for at least 30 days.

News Market Reaction – ACRS

+5.33%

+5.33% Session close to close

In the Apr 8 session, ACRS gained 5.33%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.3% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +5.3% in the session following this news. A strong positive reaction aligns with the company’s ongoing effort to raise visibility around its immuno‑inflammatory pipeline. Prior updates, including clinical data and financial results, sometimes saw flat or negative next‑day moves, so a sharp gain on this conference news would have stood out versus that pattern. Investors would still have needed to weigh recent equity sales, broader biotech sentiment, and the possibility that enthusiasm for event-driven exposure could fade after the webcast period.

Key Figures

Conference time: 12:00 PM EDT Webcast availability: 30 days

2 metrics

Conference time 12:00 PM EDT Scheduled fireside chat on April 14, 2026

Webcast availability 30 days Archived webcast available on company website

Historical Context

5 past events · Latest: Mar 27 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 27	Phase 2a data update	Positive	+0.0%	Presented Phase 2a ATI‑2138 ePoster showing rapid, sustained AD improvements.
Mar 20	Clinical poster notice	Neutral	-1.3%	Announced ePoster on ATI‑2138 Phase 2a at 2026 AAD Annual Meeting.
Mar 18	Trial enrollment complete	Positive	-5.7%	Completed enrollment of 109‑patient Phase 2 bosakitug atopic dermatitis trial.
Mar 03	Conference participation	Neutral	-0.3%	Planned fireside chat at Leerink Partners 2026 Global Healthcare Conference.
Feb 26	Earnings and update	Positive	-5.4%	Reported 2025 results, pipeline progress, and cash of $151.4M with runway into H2 2028.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive clinical and corporate updates have often been met with flat or negative next-day moves, suggesting a tendency for muted or contrarian reactions to news.

Recent Company History

Over the last few months, Aclaris reported multiple pipeline milestones and corporate events, including Phase 2a data for ATI‑2138, completion of enrollment in a 109‑patient Phase 2 trial of bosakitug, participation in investor conferences, and Q4/full‑year 2025 financials with cash of $151.4M and runway into H2 2028. Yet, several of these announcements coincided with flat to negative price reactions. Today’s conference-participation news fits into this pattern of frequent, largely non-dilutive updates against a backdrop of cautious trading.

Key Terms

immuno-inflammatory

1 terms

immuno-inflammatory medical

"focused on developing novel product candidates for immuno-inflammatory diseases"

Immuno-inflammatory describes processes in which the immune system causes or controls inflammation in the body — a coordinated response that can protect against infection but also drive chronic illness when overactive. Investors care because many drugs, devices and diagnostics target these pathways; success or failure in clinical trials, approvals or reimbursements for immuno-inflammatory therapies can quickly change a company’s revenue outlook, valuation and market opportunity, like fixing a faulty fire alarm that either prevents disaster or keeps dousing the house.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WAYNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday, April 14, 2026, at 12:00 PM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference.

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.

Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com

FAQ

When will Aclaris (ACRS) present at the H.C. Wainwright inflammatory skin disease conference?

Aclaris will present on April 14, 2026 at 12:00 PM EDT, in a scheduled fireside chat. According to the company, CEO Dr. Neal Walker and senior leaders will participate and discuss clinical-stage programs during the virtual event.

How can investors watch the Aclaris (ACRS) fireside chat on April 14, 2026?

Investors can watch via a live webcast on the Aclaris events page at the scheduled time. According to the company, the webcast will also be archived on the website and remain available for at least 30 days after the event.

Will the Aclaris (ACRS) webcast be available after the H.C. Wainwright conference?

Yes. The webcast will be archived and accessible after the live event for at least 30 days. According to the company, investors can view the replay on the Aclaris website Events page during that window.

Who from Aclaris (ACRS) will participate in the April 14, 2026 virtual conference session?

Aclaris said CEO Dr. Neal Walker and other senior leadership team members will participate in the fireside chat. According to the company, the group will discuss the company's clinical-stage programs and development priorities.

Where is the archived Aclaris (ACRS) webcast hosted and how long will it remain online?

The archived webcast will be hosted on the Aclaris website Events page and remain online for at least 30 days. According to the company, both the live webcast and the replay will be accessible via that Events page.